[go: up one dir, main page]

AP3536A - Method of treating atrial fibrillation - Google Patents

Method of treating atrial fibrillation

Info

Publication number
AP3536A
AP3536A AP2012006331A AP2012006331A AP3536A AP 3536 A AP3536 A AP 3536A AP 2012006331 A AP2012006331 A AP 2012006331A AP 2012006331 A AP2012006331 A AP 2012006331A AP 3536 A AP3536 A AP 3536A
Authority
AP
ARIPO
Prior art keywords
atrial fibrillation
treating atrial
treating
fibrillation
atrial
Prior art date
Application number
AP2012006331A
Other languages
English (en)
Other versions
AP2012006331A0 (en
Inventor
Charles Antzelevitch
Luiz Belardinelli
Alexander Burashnikov
John Shryock
Dewan Zeng
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43736345&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP3536(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of AP2012006331A0 publication Critical patent/AP2012006331A0/xx
Application granted granted Critical
Publication of AP3536A publication Critical patent/AP3536A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Epoxy Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AP2012006331A 2009-12-21 2010-12-20 Method of treating atrial fibrillation AP3536A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28873909P 2009-12-21 2009-12-21
PCT/US2010/061257 WO2011084733A1 (en) 2009-12-21 2010-12-20 Method of treating atrial fibrillation

Publications (2)

Publication Number Publication Date
AP2012006331A0 AP2012006331A0 (en) 2012-06-30
AP3536A true AP3536A (en) 2016-01-13

Family

ID=43736345

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2012006331A AP3536A (en) 2009-12-21 2010-12-20 Method of treating atrial fibrillation

Country Status (36)

Country Link
US (3) US8513254B2 (es)
EP (2) EP2749282B1 (es)
JP (2) JP5723889B2 (es)
KR (2) KR20160108611A (es)
CN (3) CN102665713B (es)
AP (1) AP3536A (es)
AR (1) AR079552A1 (es)
AU (1) AU2010339753B2 (es)
BR (1) BR112012015499A2 (es)
CA (1) CA2784028C (es)
CL (1) CL2012001597A1 (es)
CR (1) CR20120353A (es)
CY (1) CY1116511T1 (es)
DK (1) DK2515900T3 (es)
EA (2) EA201691336A1 (es)
EC (1) ECSP12012004A (es)
ES (2) ES2540093T3 (es)
HR (1) HRP20150644T1 (es)
HU (1) HUE026916T2 (es)
IL (1) IL220152A (es)
ME (1) ME02179B (es)
MX (2) MX2012007052A (es)
NO (1) NO2749282T3 (es)
NZ (2) NZ600718A (es)
PE (1) PE20121520A1 (es)
PL (2) PL2515900T3 (es)
PT (2) PT2749282T (es)
RS (1) RS54118B1 (es)
SG (3) SG181541A1 (es)
SI (2) SI2515900T1 (es)
SM (1) SMT201500171B (es)
TW (1) TWI508726B (es)
UA (1) UA109887C2 (es)
UY (1) UY33119A (es)
WO (1) WO2011084733A1 (es)
ZA (1) ZA201204608B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003099281A2 (en) 2002-05-21 2003-12-04 Cv Therapeutics, Inc. Administration of a partial fatty acid inhibitor such as ranolazine for the treatment of diabetes
LT2464645T (lt) 2009-07-27 2017-10-25 Gilead Sciences, Inc. Kondensuoti heterocikliniai junginiai, kaip jonų kanalų moduliatoriai
AU2010276522B2 (en) 2009-07-29 2016-03-10 Icu Medical, Inc. Fluid transfer devices and methods of use
WO2011135582A2 (en) * 2010-04-28 2011-11-03 Cadila Healthcare Limited Pharmaceutical compositions of dronedarone
US8703759B2 (en) 2010-07-02 2014-04-22 Gilead Sciences, Inc. Fused heterocyclic compounds as ion channel modulators
KR20140033377A (ko) 2011-05-10 2014-03-18 길리애드 사이언시즈, 인코포레이티드 나트륨 채널 조절제로서의 융합된 헤테로시클릭 화합물
UY34171A (es) 2011-07-01 2013-01-31 Gilead Sciences Inc Compuestos heterocíclicos fusionados como moduladores del canal iónico
NO3175985T3 (es) 2011-07-01 2018-04-28
EP2806865A1 (en) * 2012-01-27 2014-12-03 Gilead Sciences, Inc. Combination therapies using late sodium ion channel blockers and potassium ion channel blockers
WO2014179764A1 (en) * 2013-05-03 2014-11-06 Gilead Sciences, Inc. Method of treating atrial fibrillation
SG11201600104VA (en) * 2013-08-02 2016-02-26 Gilead Sciences Inc Pharmaceutical compositions of ranolazine and dronedarone
EP3068440B1 (en) * 2013-11-15 2020-01-08 Northwestern University Inhibition of oxidative stress in atrial fibrillation
SG11201604457XA (en) 2013-12-19 2016-07-28 Gilead Sciences Inc Fused heterocyclic compounds as ion channel modulators
CN104951870B (zh) * 2015-06-01 2018-11-13 南通科瑞斯生物医药科技有限公司 药物临床前心脏风险评估方法
US20190119236A1 (en) 2016-02-23 2019-04-25 Portola Pharmaceuticals, Inc. Compounds for binding proprotein convertase subtilisin/kexin type 9 (pcsk9)
JP2019510752A (ja) 2016-03-04 2019-04-18 ギリアード サイエンシーズ， インコーポレイテッド オートタキシン阻害剤の組成物及び合剤
US10575744B2 (en) 2017-02-24 2020-03-03 Medtronic Cryocath Lp Pericardial balloon mapping
US10799703B2 (en) * 2017-12-22 2020-10-13 Medtronic, Inc. Evaluation of his bundle pacing therapy
EP3530182B1 (en) * 2018-02-27 2020-12-09 Nokia Technologies Oy Apparatus and method for determining a change in left ventricular twist of a subject's heart
KR20230141905A (ko) * 2018-07-16 2023-10-10 길리애드 사이언시즈, 인코포레이티드 Hiv의 치료를 위한 캡시드 억제제
AU2020212054B2 (en) * 2019-01-24 2025-06-12 Northwestern University Gene therapy treatment of atrial fibrillation
CN118369316A (zh) 2021-12-03 2024-07-19 吉利德科学公司 Hiv病毒感染的治疗性化合物
PL4445900T3 (pl) 2021-12-03 2025-09-22 Gilead Sciences, Inc. Związki terapeutyczne przeciwko zakażeniu wirusem hiv

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009150535A1 (en) * 2008-06-10 2009-12-17 Sanofi-Aventis Dronedarone for the prevention of permanent atrial fibrillation

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US4567264A (en) 1983-05-18 1986-01-28 Syntex (U.S.A.) Inc. Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
ES2091211T3 (es) 1989-06-23 1996-11-01 Syntex Inc Ranolazina y piperazinas relacionadas utilizadas en el tratamiento de tejidos que sufren una lesion fisica o quimica.
FR2665444B1 (fr) 1990-08-06 1992-11-27 Sanofi Sa Derives d'amino-benzofuranne, benzothiophene ou indole, leur procede de preparation ainsi que les compositions les contenant.
US5455045A (en) 1993-05-13 1995-10-03 Syntex (U.S.A.) Inc. High dose formulations
ZA953078B (en) * 1994-04-28 1996-01-05 Alza Corp Effective therapy for epilepsies
FR2764800B1 (fr) 1997-06-23 1999-09-10 Sanofi Sa Composition pharmaceutique solide contenant des derives de benzofuranne
US6303607B1 (en) 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation
AU2001278045B2 (en) * 2000-07-27 2006-08-03 Pharmacia Corporation Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure
FR2817750B1 (fr) 2000-12-11 2003-02-21 Sanofi Synthelabo Composition pharmaceutique de dronedarone pour administration parenterale
EP1347756B1 (en) 2000-12-27 2006-03-08 Genzyme Corporation Controlled release of anti-arrhythmic agents from a biodegradable hydrogel for local application to the heart
IL159614A0 (en) * 2001-07-20 2004-06-01 Karobio Ab Benzofuran derivatives and pharmaceutical compositions containing the same
US20060003002A1 (en) * 2003-11-03 2006-01-05 Lipocine, Inc. Pharmaceutical compositions with synchronized solubilizer release
US7772232B2 (en) 2004-04-15 2010-08-10 Bristol-Myers Squibb Company Quinazolinyl compounds as inhibitors of potassium channel function
GEP20094784B (en) 2005-01-06 2009-09-25 Cv Therapeutics Inc Sustained release pharmaceutical formulations
WO2007053610A2 (en) 2005-11-01 2007-05-10 The Regents Of The University Of California Methods of treating atrial fibrillation wtih pirfenidone
JP2010518169A (ja) * 2007-02-13 2010-05-27 ギリアード・パロ・アルト・インコーポレイテッド 心血管疾患の処置のためのラノラジンの使用
US20090247535A1 (en) * 2008-03-26 2009-10-01 Duke University Use of ranolazine for non-cardiovascular disorders
JP2012502047A (ja) 2008-09-04 2012-01-26 ギリアード サイエンシーズ， インコーポレイテッド 心房細動を治療する方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009150535A1 (en) * 2008-06-10 2009-12-17 Sanofi-Aventis Dronedarone for the prevention of permanent atrial fibrillation

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ANTZELEVITCH C. et al., "Atrial-selective sodium channel block as a novel strategy for the management of atrial fibrillation", Journal of Electrocardiology, 1 November 2009, Vol. 42, No. 6, pages 543-548 *
FOR THE ERATO STUDY INVESTIGATORS ET AL: "Dronedarone for the control of ventricular rate in permanent atrial fibrillation: The Efficacy and safety of dRonedArone for The cOntrol of ventricular rate during atrial fibrillation (ERATO) study", AMERICAN HEART JOURNAL, vol. 156, no. 3, September 2008 (2008-09-01), MOSBY- YEAR BOOK INC, US, pages 527.E1 - 527.E9, XP025470440 *
GRAMLEY FELIX ET AL: "Recent advances in the pharmacological treatment of cardiac arrythmias.", DRUGS OF TODAY, vol. 45, no. 11, November 2009 (2009-11-01), BARCELONA, SPAIN, pages 807 - 824, XP002631257 *
KUMAR KAPIL ET AL: "New and emerging antiarrhythmic drugs for atrial fibrillation: what may become available to the clinician in the near future.", CURRENT TREATMENT OPTIONS IN CARDIOVASCULAR MEDICINE, vol. 11, no. 5, October 2009 (2009-10-01), pages 373 - 380, XP002631255 *
SCIRICA BENJAMIN M ET AL: "Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of Arrhythmias in patients with Non-ST-Segment-Elevation acute coronary syndrome - Thrombolysis in myocardial infarction 36 (MERLIN-TIMI 36) Randomized controlled trial", CIRCULATION, vol. 116, no. 15, October 2007 (2007-10-01), pages 1647 - 1652, XP002631256 *

Also Published As

Publication number Publication date
EP2749282A1 (en) 2014-07-02
PL2515900T3 (pl) 2015-10-30
AP2012006331A0 (en) 2012-06-30
EP2515900B1 (en) 2015-04-29
AR079552A1 (es) 2012-02-01
EP2515900A1 (en) 2012-10-31
ES2540093T3 (es) 2015-07-08
HK1170675A1 (en) 2013-03-08
EP2749282B1 (en) 2017-08-09
SI2515900T1 (sl) 2015-07-31
AU2010339753B2 (en) 2015-01-22
CN104147010A (zh) 2014-11-19
MX2012007052A (es) 2012-07-30
CA2784028A1 (en) 2011-07-14
KR20160108611A (ko) 2016-09-19
US8754087B2 (en) 2014-06-17
PL2749282T3 (pl) 2018-01-31
IL220152A0 (en) 2012-07-31
ECSP12012004A (es) 2012-08-31
SG181541A1 (en) 2012-07-30
UA109887C2 (uk) 2015-10-26
KR20120107995A (ko) 2012-10-04
CN104688739A (zh) 2015-06-10
US20130317038A1 (en) 2013-11-28
HUE026916T2 (en) 2016-08-29
JP2013515007A (ja) 2013-05-02
CL2012001597A1 (es) 2013-06-28
SG10201408528RA (en) 2015-04-29
TWI508726B (zh) 2015-11-21
UY33119A (es) 2011-07-29
SG10201710751TA (en) 2018-02-27
ZA201204608B (en) 2013-02-27
NZ600718A (en) 2014-08-29
CY1116511T1 (el) 2017-03-15
AU2010339753A1 (en) 2012-07-12
WO2011084733A1 (en) 2011-07-14
JP5723889B2 (ja) 2015-05-27
EA201290451A1 (ru) 2013-01-30
US9056108B2 (en) 2015-06-16
US20140323493A1 (en) 2014-10-30
SI2749282T1 (sl) 2017-12-29
ES2646603T3 (es) 2017-12-14
DK2515900T3 (en) 2015-07-27
IL220152A (en) 2016-11-30
SMT201500171B (it) 2015-09-07
EA025445B1 (ru) 2016-12-30
CA2784028C (en) 2016-08-23
RS54118B1 (sr) 2015-12-31
PT2749282T (pt) 2017-11-15
PT2515900E (pt) 2015-07-30
US20110183990A1 (en) 2011-07-28
NZ627181A (en) 2016-02-26
MX344329B (es) 2016-12-13
TW201136586A (en) 2011-11-01
US8513254B2 (en) 2013-08-20
EA201691336A1 (ru) 2017-05-31
BR112012015499A2 (pt) 2016-05-03
HRP20150644T1 (hr) 2015-07-31
JP2015057449A (ja) 2015-03-26
PE20121520A1 (es) 2012-11-26
NO2749282T3 (es) 2018-01-06
CN102665713B (zh) 2015-02-18
CN102665713A (zh) 2012-09-12
CR20120353A (es) 2014-10-07
ME02179B (me) 2015-10-20

Similar Documents

Publication Publication Date Title
AP3536A (en) Method of treating atrial fibrillation
EP2558014A4 (en) Methods and devices for treating atrial fibrillation
EP2421607A4 (en) DEVICE AND METHOD FOR PROOFING AND TREATING PREVIOUS LAYOUMS
IL208354A0 (en) Methods of treatment
EP2313103A4 (en) PROCESS FOR TREATING A BLÉPHARITE
IL214664A0 (en) Methods of treating hair related conditions
GB201018147D0 (en) Method of treatment
PL2501381T3 (pl) Leczenie migotania przedsionków
GB201003920D0 (en) Method of treatment
EP2300496A4 (en) ATHEROSCLEROSIS TREATMENT METHODS
ZA201108493B (en) Method of treating hair
ZA201005206B (en) Method of treating hair
GB201018149D0 (en) Method of treatment
EP2585103A4 (en) METHOD OF TREATMENT
IL216456A0 (en) Method of treating frailty
GB201020015D0 (en) Method of treatment
EP2424539A4 (en) PROCESS FOR TREATING DEPRESSION
EP2306838A4 (en) METHOD FOR THE TREATMENT OF ATHEROSCLEROSIS
HK1158972A (en) Method of treating atrial fibrillation
AU2011904917A0 (en) Method for preventing and/or treating atrial fibrillation
HK1182299A (en) Methods and devices for treating atrial fibrillation
GB0823435D0 (en) Method of treatment
GB0921823D0 (en) Method of treatment
GB0909807D0 (en) Method of treatment
GB0904164D0 (en) Method of treatment